Rhythm Biosciences (ASX:RHY) said initial testing validated the efficacy of its second-generation ColoSTAT diagnostic kit for bowel cancer, according to a Monday filing with the Australian bourse.
Following a serum sample test, the second-generation kit recorded a 0.805 performance value, compared with 0.784 for the first-generation test kit.
Over the coming weeks, the medical diagnostics company will work with contract manufacturing organization, Quansys, to produce the beta version of the assay to develop the commercial version of the algorithm and further verification and validation, the filing said.
Shares of Rhythm Biosciences surged almost 45% at market close on Monday.
Price (AUD): $0.11, Change: $+0.034, Percent Change: +44.74%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.